Company intelligence / Profile preview

MAVIDx

Miami, Florida, United States

Ownership: Private
Development stage: Other

Overview

MAVIDx is a U.S.-based biotechnology start-up focused on ultra-high-throughput infectious disease diagnostics, initially for COVID-19, influenza, and RSV. Its core platform employs proprietary molecular barcoding multiplex technology, spun off from NanoString, and is being validated on the nCounter system licensed from Veracyte, aiming for regulatory approval. The company's platform is capable of processing over 40,000 samples per day for respiratory viruses.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic test
Industry: Molecular Diagnostics

Partnerships

Veracyte

Beyond the preview

Go deeper on MAVIDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAVIDx.

Explore the full profile